Discover Yttrium-90 (Y90): The "Nuclear Weapon" for precise liver tumor targeting.
Read our latest blog featuring Dr. Zheng Xin to see how China is opening doors to advanced interventional oncology.
Read more:zurl.co/aWdZt
#Y90 #LiverCancer #Oncology #China
Did you know it’s Interventional Oncology (IO) Awareness Week?
ABK Biomedical is proud to support & contribute to the growing field of IO with an innovative approach to radioembolization with Eye90 microspheres® and our Route90 clinical trial.
www.ioawareness.org
#IOAwarenessWeek #Y90 #IKnowIO
ABK Biomedical is now on BlueSky! Come chat with us and learn more about how EYE90 fits into the treatment of HCC. #interventionaloncology #precisionmedicine #Y90 #cancertherapies www.abkbiomedical.com
1/5 🚨 The CIRSE CIRT-FR Registry reports a 13% serious adverse event rate in TARE Y90 therapy for liver cancers in France! 📊🔬
Explore the latest study from CVIR on outcomes of radioembolisation in HCC and colorectal liver metastases (CRLM) 🧵👇
#Y90
💡Spotlight on Ep.2- How to Simplify Dosing: Y90 Dosimetry from Simple to Complex with expert interventional radiologists, who share insights on dosing strategies based on lesion characteristics
www.youtube.com/watch?si=lKt...
#ONC2 #Y90 #TARE #HCC #OncSky #RadSky #LiverCancer @backtable.bsky.social
2/5 Y-90 radioembolization and ICIs come with limitations:
- Y-90: Low response rates
- ICIs: Out-of-field recurrence risk
Together, they could counteract each other's weaknesses, leading to more effective HCC treatments.
#Y90 #Immunotherapy #CancerTreatment
Honoured to participate in the conference and deliver a talk about TARE Therapy for HCC management at Yashoda Hospital Hyderabad.
Thank you Dr Venkat @GottipatiVenki for invitation and the initiative.
#TARE #Y90 #InterventionalRadiology #DrKaloo #MaxHealthcare
